The fourth IACT review meeting took place on October 25-26, 2017 in London, United Kingdom....
In his new position, Juan will be responsible for raising investment capital, providing strategic leadership and overseeing operations for the Company. Juan brings more than 18 years of experience in the sector having previously served as Business Development Partner at Biolty (Madrid, Spain), prior to that Juan was Director of the industrial affairs department at the CEU University (Valencia, Spain) and head of oncology group at Astellas/Agensys (Santa Monica, CA, USA) and Bristol Myers Squibb (Princeton, NJ, USA). Juan earned a M.S. in biochemistry and a Ph.D.
The IACT Kick-off meeting took place November 12, 2013 in Frankfurt, Germany. Representatives of all partners, including all general assembly members and representatives of management team participated in the meeting.
European Framework programmes (FPs) are the European Union’s main instrument for funding European Medical Research. They support the creation of multidisciplinary networks designed to promote the collaboration of health-related industries and integrate European-wide research, “as well as build a ‘critical mass’ of expertise and excellence”.
LeadArtis S.L. announced the generation of multivalent and multispecific trimerbodies. By fusing single-chain variable fragments(scFv) with the same or different specificity to both N- and C-terminus of the trimerizing scaffold domain, monospecific or bispecific hexavalent molecules were successfully produced and secreted as soluble proteins by transfected mammalian cells.
This past 19-21 September, the Bilbao Exhibition Center hosted the BIOSPAIN 2012 Investment Forum. The Investment Forum offers a unique setting with pan-European networking for top entrepreneurs, R&D leaders, investors and experts from the Biotech sector. Companies seeking international financing or partners have the opportunity to present their business projects to a panel of interested investors and corporate partners.
LeadArtis S.L. announced that published proof-of-concept data with a new Trimerbody® molecule. Trimerbody® molecules based in human collagen XV exhibited excellent antigen binding capacity, and demonstrated greater thermal and serum stability and resistance to protease digestion than conventional type XVIII Trimerbody® molecules.
The Immunotherapy Network IMMUNONET is a project approved under the Programme of Territorial Cooperation of the European Southwest Area (SUDOE-Interreg IV B). Bringing together leading international scientists, a stable team of cutting-edge research in Immunotherapy has been established in the southwestern Europe.
This past 3 November, the Medical Association of Barcelona (COMB) hosted the fifth edition of the Healthcare Investment Forum, a conference which aims to make private funding more accessible to companies in the healthcare sector that are in the growth phase and require an injection of up to 3 million euros of capital. Leadartis was one of the 11 companies selected, from more than 30 candidates, to present the project to more than 100 venture investors.
The Center for Industrial Technological Development (www.cdti.es), a Spanish governmental body dependent on the Ministry of Science and Innovation has granted a NEOTEC loan to Leadartis for the development of diagnostic and therapeutic candidates.
Click here for more information
LeadArtis participates in the fourth Immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) meeting in London (UK)
31-10-2017
The fourth IACT review meeting took place on October 25-26, 2017 in London, United Kingdom.... |
LeadArtis discloses ATTACK, a novel bispecific T cell-recruiting antibody approach for cancer immunotherapy
15-01-2018
LeadArtis´scientists, in collaboration with other prime... |
Leadartis successfully accomplishes the TERET project
07-04-2017
Leadartis is proud to announce the successful conclusion of the TERET (New Treatments for... |